Thrombotic microangiopathy

This study tests whether adding ianalumab to standard eltrombopag treatment helps adults with immune thrombocytopenia (ITP) who did not get better with steroids. ITP causes low platelet counts, raising bleeding risk. The trial involves 152 participants and measures how long the t…

This phase 3 trial tests whether adding ianalumab (a biologic drug) to standard corticosteroids helps adults with newly diagnosed immune thrombocytopenia (ITP) achieve a stable platelet response off all treatments at 12 months. About 226 participants will receive either ianalumab…

This study planned to test the drug eculizumab in cancer patients who developed kidney damage from the chemotherapy drug gemcitabine. The goal was to see if eculizumab could help the kidneys recover. However, the trial was withdrawn before any patients were enrolled, so no data w…

This study planned to test whether infusions of mesenchymal stem cells could safely help people with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial was withdrawn before enrolling any participants, so n…

This study looks back at how doctors in Germany prescribed caplacizumab (Cablivi) for acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood clotting disorder. Researchers will analyze data from 350 patients to see how well the drug works outside of clinical trials and…

This study tests a new medicine called crovalimab for people with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots and kidney damage. The trial includes 83 adults and teens who receive the drug to see if it can control the disease and impr…

This phase 2 trial tests whether the drug itacitinib, given with standard care, can prevent graft-versus-host disease (GVHD) in people who receive a donor stem cell transplant for blood cancers. GVHD happens when the donor cells attack the patient's body. The study includes 31 ad…

This phase 2 trial tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants have already tried steroids and another standard treatment. The study mea…

This study tests a medicine called TAK-755 in people with a rare inherited blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP). The condition causes dangerous blood clots and bleeding. TAK-755 replaces a missing enzyme to help prevent or treat these episod…

This phase 3 trial tests crovalimab in 41 children with atypical hemolytic uremic syndrome (aHUS), a rare disease that causes blood clots and kidney damage. The drug is given first through a vein, then as a shot under the skin every four weeks. The goal is to see if it can stop d…

This program provides narsoplimab, an experimental drug, to patients who develop a serious blood clotting condition called thrombotic microangiopathy after a stem cell transplant. The goal is to offer treatment when no other options are available. Patients must have had a stem ce…

This study tests whether adding diammonium glycyrrhizinate (a liver-protecting compound) to standard high-dose dexamethasone can improve platelet counts in adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing b…

This study tests a drug called efgartigimod given as a shot under the skin for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if the drug is safe and helps maintain safe platele…

This study tests whether N-acetylcysteine (NAC), a common antioxidant, can treat a severe blood vessel condition called TA-TMA that can happen after a stem cell transplant. Current treatments are either ineffective or very expensive. The trial will enroll 44 adults diagnosed with…

This study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited fr…

This study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…

This study is testing a new, faster blood test for diagnosing acquired thrombotic thrombocytopenic purpura (aTTP), a rare but life-threatening blood clotting disorder. The new test, called HemosIL AcuStar, will be compared to two existing tests in 500 patients from Spain and Port…

This study tests whether a treatment called IVIG (intravenous immunoglobulin) can help with ongoing neurological symptoms after COVID-19, like dizziness, trouble walking, or memory problems. About 45 adults who had COVID-19 at least 12 weeks ago will receive either IVIG or a plac…

This pilot study tests whether a daily mindful music listening program is practical and acceptable for patients hospitalized after an allogeneic stem cell transplant. About 35 adults will listen to music for one hour each day using a web-based platform. The study measures how fea…

This study looks at whether adding art therapy to physical therapy can help children aged 5 to 18 recover emotionally and physically after a stem cell transplant. For two weeks, some children receive both art and physical therapy daily, while others get only physical therapy. Res…

This study evaluates whether artificial intelligence models can accurately interpret ROTEM blood clotting tests and recommend treatments for coagulopathy. Researchers will compare AI decisions to those of a panel of clinical experts using data from adults undergoing elective card…

This study aims to measure damage to tiny blood vessels in people with thrombotic thrombocytopenic purpura (TTP), both during active disease and in remission. Researchers will use brain MRI, eye scans, and nailfold capillary exams to detect abnormalities. 79 participants will be …

This study follows 50 young men who had cancer or blood disorders as children and received treatments that can harm fertility. Some stored testicular tissue before treatment; others did not. Researchers will check their fertility through exams, ultrasounds, blood tests, and semen…

This study observes 367 Chinese patients with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. Researchers will track how patients are treated in routine care and monitor their health for up to 12-24 months. The goal is to bet…

This study aims to develop better lab tests to diagnose and monitor two rare kidney diseases: atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). Researchers will analyze blood, cells, and kidney tissue from 180 patients and healthy volunteers to find markers t…